BACKGROUND: The Mirasol system for whole blood (WB) is a non-toxic, non-mutagenic pathogen reduction technology (PRT) that treats WB units with riboflavin (vitamin B<sub>2</sub>) and ultraviolet (UV) light to alter nucleic acids, thereby reducing pathogen infectivity and inactivating white blood cells. This study evaluates the quality of red blood cells (RBCs) derived from WB treated with the Mirasol system. STUDY DESIGN AND METHODS: Paired units of WB were collected from 61 healthy donors. One unit per donor was treated with riboflavin and UV light and the other was used as an untreated control. RBCs were processed from the WB units and stored in AS-3 at 1-6°C for 21 days and sampled for in vitro analyses of RBC quality parameters. RESULTS: Several statistically significant differences were observed between test and control units, but values were overall within normal clinical ranges. After leukoreduction, the residual leukocyte count and RBC recovery met FDA requirements. The RBC units derived from treated WB maintained haemolysis below 1% through 21 days of storage. CONCLUSION: RBCs derived from WB treated with the Mirasol system meet accepted FDA guidelines for RBC quality through 21 days of storage at 1-6°C.
BACKGROUND: The Mirasol system for whole blood (WB) is a non-toxic, non-mutagenic pathogen reduction technology (PRT) that treats WB units with riboflavin (vitamin B<sub>2</sub>) and ultraviolet (UV) light to alter nucleic acids, thereby reducing pathogen infectivity and inactivating white blood cells. This study evaluates the quality of red blood cells (RBCs) derived from WB treated with the Mirasol system. STUDY DESIGN AND METHODS: Paired units of WB were collected from 61 healthy donors. One unit per donor was treated with riboflavin and UV light and the other was used as an untreated control. RBCs were processed from the WB units and stored in AS-3 at 1-6°C for 21 days and sampled for in vitro analyses of RBC quality parameters. RESULTS: Several statistically significant differences were observed between test and control units, but values were overall within normal clinical ranges. After leukoreduction, the residual leukocyte count and RBC recovery met FDA requirements. The RBC units derived from treated WB maintained haemolysis below 1% through 21 days of storage. CONCLUSION: RBCs derived from WB treated with the Mirasol system meet accepted FDA guidelines for RBC quality through 21 days of storage at 1-6°C.
Authors: Raymond P Goodrich; Krishna K Murthy; Suzann K Doane; Christy N Fitzpatrick; La Shayla Morrow; Patricia A Arndt; Heather L Reddy; Kimberley A Buytaert-Hoefen; George Garratty Journal: Transfusion Date: 2008-10-14 Impact factor: 3.157
Authors: Loren D Fast; Martha Nevola; Jennifer Tavares; Heather L Reddy; Ray P Goodrich; Susanne Marschner Journal: Transfusion Date: 2012-05-21 Impact factor: 3.157
Authors: K Serrano; D Chen; A L Hansen; E Levin; T R Turner; J D R Kurach; J P Acker; D V Devine Journal: Vox Sang Date: 2013-12-12 Impact factor: 2.144
Authors: Laura Tonnetti; Aaron M Thorp; Heather L Reddy; Shawn D Keil; Raymond P Goodrich; David A Leiby Journal: Transfusion Date: 2012-07-13 Impact factor: 3.157
Authors: Michał Bubiński; Agnieszka Gronowska; Paweł Szykuła; Agnieszka Woźniak; Aleksandra Rodacka; Scott Santi; Marcia Cardoso; Elżbieta Lachert Journal: Blood Transfus Date: 2022-02-01 Impact factor: 5.752